Literature DB >> 20467363

Clinical value of TSH receptor antibodies measurement in patients with Graves' orbitopathy.

A Eckstein1, J Esser, K Mann, M Schott.   

Abstract

Graves' orbitopathy (GO) is part of an autoimmune disease, in which TSH-receptor antibodies (TRAb) stimulate the target organs. Most of these patients develop hyperthyroidism and about half an orbitopathy. To ensure the diagnosis, TRAb are determined, especially in patients with GO without associated thyroid disease. Because of their significantly improved sensitivity and equal specificity, second generation TRAb-assays should be preferred. Persisting high TRAb levels are associated with a severe course of GO. TRAb cut off levels are available for prognostic statements during the course of GO and can be applied for crucial treatment decisions. Persisting high TRAb levels are also associated with low remission rates of hyperthyroidism. TRAb cut off levels are available for prognostic statements at 6, 12 and 18 months after the beginning of antithyroid drug treatment. Definitive treatment of the thyroid can be decided early on this basis, which is an advantage for ophthalmosurgical rehabilitation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20467363

Source DB:  PubMed          Journal:  Pediatr Endocrinol Rev        ISSN: 1565-4753


  6 in total

1.  Spontaneous improvement of untreated mild Graves' ophthalmopathy: Rundle's curve revisited.

Authors:  Francesca Menconi; Maria Antonietta Profilo; Marenza Leo; Eleonora Sisti; Maria Antonietta Altea; Roberto Rocchi; Francesco Latrofa; Marco Nardi; Paolo Vitti; Claudio Marcocci; Michele Marinò
Journal:  Thyroid       Date:  2013-12-09       Impact factor: 6.568

2.  Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.

Authors:  E Sisti; F Menconi; M Leo; M A Profilo; T Mautone; B Mazzi; R Rocchi; F Latrofa; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2015-01-18       Impact factor: 4.256

3.  Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy.

Authors:  K A Ponto; T Diana; H Binder; N Matheis; S Pitz; N Pfeiffer; G J Kahaly
Journal:  J Endocrinol Invest       Date:  2015-03-04       Impact factor: 4.256

Review 4.  Clinical review: Clinical utility of TSH receptor antibodies.

Authors:  Giuseppe Barbesino; Yaron Tomer
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

Review 5.  Thyroid-Associated Orbitopathy and Biomarkers: Where We Are and What We Can Hope for the Future.

Authors:  Natacha Turck; Simone Eperon; Maria De Los Angeles Gracia; Aurélie Obéric; Mehrad Hamédani
Journal:  Dis Markers       Date:  2018-03-15       Impact factor: 3.434

6.  Diagnosis, Follow-Up and Treatment Results in Thyroid Ophthalmopathy.

Authors:  Esra Savku; Kaan Gündüz
Journal:  Turk J Ophthalmol       Date:  2015-08-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.